| Literature DB >> 35811583 |
Hon-Fan Lai1, Yi-Ming Shyr1, Bor-Shiuan Shyr1, Shih-Chin Chen1, Shin-E Wang1, Bor-Uei Shyr1.
Abstract
Background and Aims: There is no consensus on the superiority of robotic distal pancreatectomy (RDP) over laparoscopic distal pancreatectomy (LDP).Entities:
Keywords: distal pancreatectomy; laparoscopic; preservation; robotic; spleen
Year: 2022 PMID: 35811583 PMCID: PMC9251888 DOI: 10.1002/hsr2.712
Source DB: PubMed Journal: Health Sci Rep ISSN: 2398-8835
Demographics of patients undergoing robotic and laparoscopic distal pancreatectomy
| Total | RDP | LDP |
| |
|---|---|---|---|---|
| Case number | 177 | 65 | 112 | |
| Gender | 0.753 | |||
| Female | 104 (58.8%) | 37 (56.9%) | 67 (59.8%) | |
| Age, y/o | 0.643 | |||
| Median (range) | 59 (23–85) | 62 (25–85) | 58 (23–84) | |
| Mean ± SD | 57 ± 15 | 58 ± 15 | 57 ± 16 | |
| BMI, | 0.074 | |||
| Median (range) | 23.4 (15.9–42.4) | 22.8 (15.9–29.4) | 23.6 (17.1–42.4) | |
| Mean ± SD | 23.9 ± 3.6 | 23.3 ± 3.0 | 24.3 ± 3.0 | |
| Tumor size, cm | 0.842 | |||
| Median (range) | 3.8 (0.9–15.0) | 3.5 (1.0–15.0) | 4.0 (0.9–13.0) | |
| Mean ± SD | 4.4 ± 2.4 | 4.3 ± 2.6 | 4.4 ± 2.3 | |
| Primary tumor | 0.814 | |||
| Pancreatic adenocarcinoma | 57 (32.2%) | 18 (27.7%) | 39 (34.8%) | |
| Serous cystadenoma | 36 (23.0%) | 13 (20.0%) | 23 (20.5%) | |
| Neuroendocrine tumor | 24 (13.6%) | 10 (15.4%) | 14 (12.5%) | |
| Mucinous cystic neoplasm | 24 (13.6%) | 8 (12.3%) | 16 (14.3%) | |
| Solid pseudopapillary tumor | 11 (6.2%) | 4 (6.2%) | 7 (6.3%) | |
| IPMN | 8 (4.5%) | 4 (6.2%) | 4 (3.6%) | |
| Chronic pancreatitis | 1 (0.6%) | 0 | 1 (1.5%) | |
| Others | 16 (9.0%) | 7 (10.8%) | 9 (8.0%) |
RDP: robotic distal pancreatectomy.
LDP: laparoscopic distal pancreatectomy.
SD: standard deviation.
BMI: body mass index.
IPMN: intraductal papillary mucinous neoplasm.
Surgical parameters for robotic and laparoscopic distal pancreatectomy
| Total | RDP | LDP |
| |
|---|---|---|---|---|
| Conversion | 5 (2.8%) | 1 (1.5%) | 4 (3.6%) | 0.653 |
| Spleen‐preservation | 79 (45.9%) | 34 (53.1%) | 45 (41.7%) | 0.157 |
| Operation time, min | ||||
| Total, | 172 | 64 | 108 | |
| Median (range) | 186 (60– 570) | 162(66–570) | 210 (60–510) | 0.005 |
| Mean ± SD | 222 ± 108 | 192 ± 108 | 240 ± 102 | |
| Spleen‐preservation, | 79 | 34 | 45 | |
| Median (range) | 180 (60–450) | 150 (66–426) | 180 (60–450) | 0.078 |
| Mean ± SD | 192 ± 90 | 168 ± 96 | 204 ± 84 | |
| Splenectomy, | 93 | 30 | 63 | |
| Median (range) | 240 (78–570) | 180 (78–570) | 240 (78–510) | 0.067 |
| Mean ± SD | 252 ± 114 | 216 ± 120 | 264 ± 114 | |
| Blood loss, ml | ||||
| Total, | 172 | 64 | 108 | |
| Median (range) | 55 (1–1200) | 50 (2–600) | 100 (1–1200) | 0.097 |
| Mean ± SD | 167 ± 223 | 131 ± 157 | 189 ± 253 | |
| Spleen‐preservation, | 79 | 34 | 45 | |
| Median (range) | 50 (5–550) | 50 (10–500) | 50 (5–550) | 0.814 |
| Mean ± SD | 93 ± 117 | 89 ± 120 | 95 ± 116 | |
| Splenectomy, | 93 | 30 | 63 | |
| Median (range) | 130 (1–1200) | 100 (2–600) | 135 (1–1200) | 0.180 |
| Mean ± SD | 232 ± 270 | 178 ± 182 | 259 ± 301 | |
| Radicality | 0.328 | |||
| R0 | 148 (95.5%) | 53 (93.0%) | 95 (96.9%) | |
| R1 | 1 (0.6%) | 1 (1.8%) | 0 | |
| R2 | 6 (3.9%) | 3 (5.3%) | 3 (3.1%) |
RDP: robotic distal pancreatectomy.
LDP: laparoscopic distal pancreatectomy.
SD: standard deviation.
R0: curative resection.
R1: microscopic residual cancer.
R2: gross residual cancer.
Surgical outcomes for robotic and laparoscopic distal pancreatectomy
| Total | RDP | LDP |
| |
|---|---|---|---|---|
| Case number | 172 | 64 | 108 | |
| Surgical mortality | 0 | 0 | 0 | 1.000 |
| Surgical morbidity | 61 (36%) | 20 (31%) | 41 (38%) | 0.413 |
| Clavien–Dindo classification | 0.367 | |||
| Grade 0 | 111 (65%) | 44 (69%) | 67 (62%) | |
| Grade I | 44 (26%) | 17 (27%) | 27 (25%) | |
| Grade II | 10 (6%) | 2 (3%) | 8 (7%) | |
| Grade III | 7 (4%) | 1 (2%) | 6 (6%) | |
| Grade IV | 0 | 0 | 0 | |
| Grade V (death) | 0 | 0 | 0 | |
| POPF | 0.340 | |||
| ISGPF | 37 (22%) | 11 (17%) | 26 (24%) | |
| PPH | 1.000 | |||
| ISGPS | 4 (2%) | 1 (2%) | 3 (3%) | |
| Wound infection | 3 (2%) | 0 | 3 (3%) | 0.295 |
| Chyle leakage | 23 (13%) | 10 (16%) | 13 (12%) | 0.498 |
| Hospital stay, days | 0.687 | |||
| Median (range) | 10 (3–66) | 9 (4–56) | 11 (3–66) | |
| Mean ± SD | 13 ± 10 | 13 ± 10 | 13 ± 9 | |
| Hospital cost, USD | ||||
| Median (range) | 10,729 (917–26,157) | 13,404 (10,260–26,157) | 7765 (917–10,773) | <0.001 |
| Mean ± SD | 10,953 ± 4522 | 14,618 ± 3480 | 8523 ± 3391 | |
| Intra‐operative cost, USD | <0.001 | |||
| Median (range) | 2974 (173–10,015) | 7386 (679–10,015) | 2520 (173–5007) | |
| Mean ± SD | 4310 ± 2425 | 7036 ± 1462 | 2557 ± 634 |
RDP: robotic distal pancreatectomy.
LDP: laparoscopic distal pancreatectomy.
POPF: postoperative pancreatic fistula.
ISGPF: International Study Group of Pancreatic Fistula.
PPH: post‐pancreatectomy hemorrhage.
ISGPS: International Study Group of Pancreatic Surgery.
SD: standard deviation.
USD: United States dollar.